Mochi Health LegitScript and Accreditation Status: What Patients Need to Know

What LegitScript Certification Actually Means

LegitScript is a third-party compliance company that reviews healthcare merchants, online pharmacies, and telehealth platforms against standards covering prescriber legitimacy, pharmacy compliance, and transparent pricing. A LegitScript seal tells consumers that a platform has been audited, not just self-declared safe.

The Three Tiers of LegitScript Review

LegitScript offers distinct certification programs. For telehealth companies, the relevant one is the LegitScript Telehealth Certification, which requires platforms to demonstrate that prescribers hold valid state licenses, that partner pharmacies are licensed in every state they serve, and that the platform does not dispense controlled substances without a valid prescriber-patient relationship.

A separate track covers online pharmacy certification, relevant when a telehealth company also dispenses directly. Companies that pass this review are listed publicly at legitscript.com, which you can cross-check at any time.

Why Certification Gaps Matter for GLP-1 Patients

GLP-1 receptor agonists such as semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) are prescription-only drugs. The FDA regulates their distribution, and state medical boards regulate the prescribers who order them. A telehealth company without third-party accreditation is not automatically illegal or unsafe, but it carries a different risk profile than one that has passed an external audit.

The FDA issued a safety communication in October 2023 warning patients about compounded versions of semaglutide, noting reports of dosing errors and adverse events tied to products from outsourcing facilities not subject to the same manufacturing controls as FDA-approved drugs [1]. That warning was updated in 2024 as the FDA removed semaglutide from its drug shortage list, making most compounded semaglutide legally impermissible outside of 503A/503B pathways [2].

Mochi Health's Current Accreditation Status

Mochi Health does not appear on LegitScript's public registry of certified telehealth providers as of July 2025. That absence does not constitute a violation of federal law. LegitScript certification is voluntary. However, it does mean patients cannot rely on a LegitScript audit to verify the platform's compliance posture.

BBB File and Consumer Complaints

The Better Business Bureau (BBB) profile for Mochi Health shows the company is not BBB-accredited. Consumer reviews on file include complaints in three recurring categories:

1. Billing and subscription disputes. Multiple reviewers report difficulty canceling memberships or obtaining refunds after stopping treatment.
2. Prescription fulfillment delays. Patients describe waits of several weeks for compounded GLP-1 medications, sometimes without proactive communication from the care team.
3. Asynchronous care quality. Some patients report that follow-up messages went unanswered for days, raising questions about the adequacy of clinical oversight.

The BBB is not a regulatory body, and a high complaint volume on BBB does not establish illegality. Still, the complaint patterns are consistent with structural features of high-volume, asynchronous telehealth: lean staffing, heavy reliance on messaging rather than video visits, and third-party pharmacy fulfillment outside the platform's direct control.

State Medical Board Compliance

Telehealth prescribing in the United States is governed by a patchwork of state laws. After the federal COVID-era telehealth flexibilities began expiring in 2023, most states reinstated requirements that a valid prescriber-patient relationship be established before a controlled substance or brand-name drug is prescribed. Semaglutide and tirzepatide are not controlled substances (Schedule II-V), so the prescriber-patient relationship rules are less stringent than for, say, stimulants. However, prescribers still must hold an active license in the patient's state.

You can verify any prescriber's license in approximately 60 seconds by searching the NPPES NPI Registry and then cross-checking with your state's medical board. The Federation of State Medical Boards maintains a DocInfo database for this purpose. Mochi Health lists prescriber names on patient care summaries; patients should run that check independently.

FDA Compliance and Compounded GLP-1 Medications

This is the highest-stakes compliance issue for any GLP-1 telehealth company right now.

The 2023-2024 FDA Compounding Crackdown

When branded semaglutide (Wegovy, Ozempic) faced supply shortages, the FDA placed it on the drug shortage list, temporarily allowing 503A compounding pharmacies to produce copies. Mochi Health, like dozens of other telehealth platforms, offered patients compounded semaglutide during this window.

In October 2023, the FDA published a safety alert specifically warning consumers about compounded semaglutide products, citing "reports of adverse events, some requiring hospitalization," linked to products that may have varied in concentration or contained non-approved salt forms [1]. A subsequent FDA update in February 2024 flagged semaglutide base vs. Semaglutide sodium as a source of potential dosing confusion [2].

By mid-2024, the FDA determined the branded semaglutide shortage had resolved, removing it from the shortage list. Under 21 U.S.C. 503A and 503B, most compounded copies of a non-shortage drug are no longer permissible unless a patient has a documented allergy to an inactive ingredient in the branded product. The FDA issued a compliance policy in early 2025 giving platforms a wind-down period, but enforcement timelines have continued to shift [2].

What This Means for Mochi Health Patients Specifically

Patients who received compounded semaglutide through Mochi Health during 2022-2024 were operating in a legally ambiguous but not categorically illegal space. Patients enrolling after mid-2024 should ask Mochi Health directly whether the semaglutide they are being prescribed is:

• FDA-approved branded Wegovy or Ozempic
• Tirzepatide from a 503B outsourcing facility (tirzepatide remained on the shortage list longer than semaglutide)
• Compounded semaglutide from a 503A pharmacy with a documented patient-specific need

The FDA's guidance on this distinction is available on its compounding page [2]. Getting a clear written answer before you pay protects you from receiving a product that may not meet current federal standards.

Clinical Evidence Behind the Medications Mochi Prescribes

Whether a telehealth platform is accredited or not, the underlying medications carry the same evidence base. Patients deserve a clear picture of what that evidence shows.

Semaglutide 2.4 mg (Wegovy)

The STEP-1 trial (N=1,961) showed semaglutide 2.4 mg subcutaneous once weekly produced a mean body weight reduction of 14.9% at 68 weeks versus 2.4% with placebo (P<0.001) [3]. The SELECT cardiovascular outcomes trial (N=17,604) showed a 20% reduction in major adverse cardiovascular events (MACE) in adults with obesity and pre-existing cardiovascular disease over a median follow-up of 34.2 months [4].

Tirzepatide 15 mg (Zepbound)

The SURMOUNT-1 trial (N=2,539) showed tirzepatide 15 mg produced a mean weight loss of 20.9% at 72 weeks versus 3.1% with placebo (P<0.001) [5]. This is the largest mean weight loss demonstrated in any phase 3 trial of an injectable weight-loss agent to date.

What the Evidence Does Not Tell You

Trial participants received consistent, protocol-driven dosing escalation and close monitoring by research teams. Telehealth platforms that rely primarily on asynchronous messaging may not replicate that level of clinical oversight. The American Association of Clinical Endocrinology (AACE) 2023 obesity guidelines state: "Pharmacologic therapy for obesity should be initiated and monitored by clinicians with training in obesity medicine or endocrinology, with regular in-person or synchronous telehealth follow-up" [6]. Asynchronous-only care models may fall short of that standard.

How Mochi Health's Business Model Works

Mochi Health positions itself as a platform combining GLP-1 prescribing with registered dietitian coaching and lifestyle support. The company accepts some commercial insurance for visits and medications, which differentiates it from fully cash-pay competitors.

Insurance vs. Cash-Pay Pathway

When insurance is used, the prescriber submits a prior authorization for branded GLP-1 medications. Success rates for GLP-1 prior authorizations vary widely. The American Diabetes Association notes that access barriers including prior authorization and step therapy affect a substantial proportion of patients who qualify for GLP-1 therapy [7]. If the prior auth fails, patients are typically offered a cash-pay compounded alternative or transition to a branded product at list price.

Membership and Subscription Fees

The cash-pay membership model involves a monthly platform fee (reported in consumer reviews as approximately $99-$129/month as of early 2025) separate from medication costs. Compounded semaglutide pricing has ranged widely across telehealth platforms, from roughly $199 to $399/month, though these figures are subject to change. Patients should request a written, itemized quote before enrolling because pricing is not always clearly disclosed on landing pages.

HealthRX 4-Question Pre-Enrollment Checklist for GLP-1 Telehealth Platforms:

Before entering payment information on any GLP-1 telehealth platform, ask these four questions in writing and get written answers:

1. Is my prescriber licensed in my state? (Verify independently via NPI Registry.)
2. Is the medication FDA-approved branded or compounded, and if compounded, from a 503A or 503B facility?
3. What is the total monthly cost including platform fees, medication, and any required labs?
4. What is the cancellation and refund policy, and is it documented in the terms of service?

A platform that cannot or will not answer all four questions in writing before you pay warrants serious caution.

Real Patient Complaint Patterns and What They Reveal

Consumer complaints about Mochi Health on the BBB, Trustpilot, and Reddit (r/Semaglutide, r/WeightLossAdvice) cluster into patterns worth examining systematically.

Billing Transparency Issues

The most common complaint category involves charges that continued after patients believed they had canceled. This is a structural problem in subscription telehealth broadly, not unique to Mochi, but the volume of these complaints is higher than for some competitors. The FTC's "Click to Cancel" rule, finalized in October 2024, requires that subscription cancellation be as easy as enrollment [8]. Mochi Health's compliance with that rule is something patients should verify by testing the cancellation flow before committing to a plan.

Clinical Oversight Concerns

A smaller but more clinically significant complaint category involves patients who experienced side effects (nausea, vomiting, injection-site reactions, tachycardia) and reported difficulty reaching a clinician in a timely way. GLP-1 medications carry FDA labeling warnings for pancreatitis, thyroid C-cell tumors (in rodents, with an unknown human risk), and acute kidney injury secondary to dehydration [9]. The FDA requires prescribers to counsel patients on these risks at initiation. An asynchronous-first care model that does not include a synchronous visit at initiation may not adequately fulfill that counseling obligation.

Positive Experiences

Not all reported experiences are negative. Many reviewers describe significant weight loss, helpful dietitian interactions, and smooth insurance coordination. The heterogeneity of outcomes likely reflects variability in which prescriber and care team a patient is assigned to, rather than uniform platform quality.

How Mochi Health Compares to Accredited Alternatives

Several GLP-1 telehealth platforms have pursued or obtained formal accreditation. Ro, Hims and Hers Health, and Done have all at various points sought LegitScript or URAC review for their telehealth operations. URAC (Utilization Review Accreditation Commission) offers a Telehealth Accreditation Program that assesses clinical protocols, patient safety, and quality management [10].

Patients who want the additional assurance of third-party accreditation should search the LegitScript public registry and the URAC accreditation directory directly. Neither list is exhaustive, and accreditation is not a guarantee of clinical quality, but it does mean an external auditor has reviewed the platform's processes.

Regulatory Red Flags to Watch for in Any GLP-1 Platform

The FDA's Office of Criminal Investigations has pursued enforcement actions against online pharmacies selling semaglutide without valid prescriptions. The key red flags across platforms include:

• No prescriber name or NPI number provided to the patient
• Medications shipped before any clinical interaction occurs
• Pricing that undercuts branded drugs by 80% or more (may signal non-FDA-approved ingredients)
• Websites that advertise "no prescription needed" or "prescription included" framing
• No published pharmacy name or state pharmacy license number

Mochi Health does not appear to exhibit the most severe of these red flags (no-prescription dispensing), but the compounded medication pathway warrants the verification steps described above. The FDA's BeSafeRx campaign provides a consumer checklist for evaluating online pharmacy legitimacy [11].

Questions to Ask Mochi Health Before Enrolling

Patients considering Mochi Health should contact the company's support team and request specific answers to the following before payment:

• Which pharmacy fulfills prescriptions, and is that pharmacy licensed in my state?
• Will I have a synchronous video or phone visit with a prescriber before my first prescription is issued?
• If my insurance denies prior authorization, what is my out-of-pocket cost and is there a compounded alternative?
• What labs are required before starting, and are lab costs included in the membership fee?
• How do I reach a clinician urgently if I experience a serious side effect?

Getting written answers to these questions, rather than relying on marketing copy, is the single most protective step a prospective patient can take.